CRLX101: Phase II ongoing

Cerulean began the second stage in 19 additional patients of an open-label, U.S. Phase II trial evaluating 15 mg/m 2 IV CRLX101 every 2 weeks in up to 29 ovarian cancer patients who have progressed following first-line platinum-based therapy. The company said the first patient to achieve 6 cycles of PFS had a 37% net reduction in tumor burden, which satisfied the criterion for a RECIST partial response and triggered the start of the second stage. The first stage enrolled 10 patients, of which 4 remain "on study" without disease progression. CRLX101 was well tolerated. ...